Medical Condition News

RSS

NHLBI grants MU $8.47 million for research on cardiovascular diseases

One of the largest medical research grants ever awarded to the University of Missouri was announced today by MU scientists and administrators. The National Institutes of Health grant will help answer important questions about such prevalent health problems as high blood pressure, diabetes and stroke. The conditions are closely associated with cardiovascular disease, which is the leading cause of death in Missouri and the nation.

7 May 2010

Sleep problems can increase depression and reduce quality of life in older people

In a study of residents of Assisted Living Facilities (ALFs) in Los Angeles showed that 65% had clinically significant sleeping problems and that poor sleep was associated with declining quality of life and increased depression over a six month follow-up period. This study is published today in the Journal of the American Geriatrics Society.

7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Researchers study effects of dark chocolates in reducing heart disease

Volunteers are to have chocolate delivered to their homes and be encouraged to eat 50g of it every day for eight weeks as part of a new research study.

7 May 2010

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

7 May 2010

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale.

7 May 2010

Swedish researchers present a new principle for inhibiting atherosclerosis

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis.

7 May 2010

Mouse study may lead to new therapies for Parkinson's disease

Endometrial stem cells injected into the brains of mice with a laboratory-induced form of Parkinson's disease appeared to take over the functioning of brain cells eradicated by the disease.

7 May 2010

Study analyzes epidemiology of falls among elderly men

Falls and fall prevention are a major concern for the elderly and people with osteoporosis, a common chronic disease which causes weak and fragile bones. People with osteoporosis are at increased risk of fracture, even after a minor fall from standing height.

7 May 2010

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801.

7 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

SCOLR Pharma, Inc. today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.

6 May 2010

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.

6 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

PurGenesis Technologies Inc. announced today positive results from a Phase I clinical trial on PUR0110, the Company's lead investigational new drug for the treatment of ulcerative colitis. This successful trial was designed to evaluate the safety and maximum tolerated dose of PUR0110.

6 May 2010

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced kidney cancers prior to partial kidney removal and reconstruction. Their findings were published in the April 2010 online edition of BJU International.

6 May 2010

Neuroscientists investigate alcohol dependency, withdrawal in C. elegans worms

Drinking alcohol over a long period of time profoundly affects the brain, which adapts to the intoxicant and causes withdrawal symptoms when consumption stops.

6 May 2010

Researchers use new tools to study how brain responds when injury occurs

Researchers at four institutions, led by Stanford University and Brown University, have begun an effort with more than $14 million of federal funding to learn both how the brain and its microcircuitry react to sudden physiological changes and what can be done to encourage recovery from injury.

6 May 2010

New study shows single night of partial sleep deprivation can induce insulin resistance

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, just one night of short sleep duration can induce insulin resistance, a component of type 2 diabetes.

6 May 2010

Study aims to clarify expression patterns of CD24 in NSCLC

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance.

6 May 2010

Medical Condition News

NHLBI grants MU $8.47 million for research on cardiovascular diseases

Sleep problems can increase depression and reduce quality of life in older people

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Researchers study effects of dark chocolates in reducing heart disease

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Swedish researchers present a new principle for inhibiting atherosclerosis

Mouse study may lead to new therapies for Parkinson's disease

Study analyzes epidemiology of falls among elderly men

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

Neuroscientists investigate alcohol dependency, withdrawal in C. elegans worms

Researchers use new tools to study how brain responds when injury occurs

New study shows single night of partial sleep deprivation can induce insulin resistance

Study aims to clarify expression patterns of CD24 in NSCLC

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News